Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 33175880.
- Also identified by DOI 10.1371/journal.pone.0242184 and PMC identifier 7657540.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.
Medical subject headings
- Coronavirus Infections
- Immunosuppressive Agents
- Ivermectin
- Pneumonia, Viral